Practical Dermatology: Atopic Dermatitis

Key Takeaways

• Completing the full 12-week induction phase led to better disease control and longer remission.

• Tapered or continued use outperformed early discontinuation across all study outcome measures.

• Researchers said the findings confirm abrocitinib’s sustained benefit in everyday clinica...

A new real-world study suggests that sustained abrocitinib treatment and adherence to the full 12-week induction phase improved outcomes and delay relapse in patients with moderate to severe atopic de...